Treatment of Borderline Personality Disorder: A Multidisciplinary Approach
S. Charles Schulz, II, MD
Professor and Head
Department of Psychiatry
University of Minnesota Medical School
Borderline Personality Disorder (BPD) is now known to be quite prevalent similar to schizophrenia and bipolar disorder. Also, BPD patients make up a significant amount of the people in psychiatric clinics and hospitals. Studies of treatments are increasing, but not necessarily integrated. These studies examine medications while others explore specific psychotherapies. There is a substantial need for knowledge of empiric studies and how to use them in practice. The goal of this session is to review current evidence and to discuss a multidisciplinary approach for Borderline Personality Disorder.
After completing this activity, participants should be able to:
- Discuss recent clinical trials and reviews of pharmacological treatments for borderline personality disorder (BPD)
- Examine the empiric support for psychotherapeutic approaches for treating Borderline Personality Disorder
- Implement strategies to integrate treatments for Borderline Personality Disorder within a multidisciplinary team approach
S. Charles Schulz, II, MD, is a consultant for Eli Lilly and Company and Bristol-Myers Squibb. Dr. Schulz has received grant support from AstraZeneca and Otsuka.
Applicable CME LLC staff have no relationships to disclose relating to the subject matter of this activity.
This activity has been independently reviewed for balance.